Enanta Achieves Milestone in Collaboration With Shionogi & Co.

Enanta Pharmaceuticals has received a milestone payment from its EP-013420 East Asia development and commercialization partner, Shionogi & Co. Ltd. The milestone reflects the initiation of Phase I studies Japan for the community antibiotic, which has been renamed S-013420 by Shionogi & Co. Ltd, for development in East Asia. First in class, EP-013420 is a Bridged Bicyclic Ketolide (BBK) that was designed by Enanta to have optimal pharmacokinetics and to provide broad treatment against respiratory pathogens, including several multi-drug resistant strains for which traditional macrolides, penicillins, and fluoroquinolones are no longer effective.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19366520&full=1)